Cargando…

Five-year analysis of the in vitro activity of tedizolid against a worldwide collection of indicated species causing clinical infections: results from the Surveillance of Tedizolid Activity and Resistance (STAR) programme

OBJECTIVES: The Surveillance of Tedizolid Activity and Resistance (STAR) programme monitored the tedizolid activity against Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, Streptococcus agalactiae and Streptococcus anginosus group. We evaluated the antimicrobial susceptibility...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carvalhaes, Cecilia G, Sader, Helio S, Streit, Jennifer M, Mendes, Rodrigo E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442614/ https://www.ncbi.nlm.nih.gov/pubmed/36072303 http://dx.doi.org/10.1093/jacamr/dlac088

Ejemplares similares

333. Tedizolid Activity against Gram-Positive Bacterial Isolates Causing Bone and Joint Infections in the United States (2015–2019)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

1547. Activity of Tedizolid and Comparator Agents against Gram-Positive Bacterial Isolates Causing Skin and Skin Structure Infections in Pediatric Patients during 2015-2019 in the US
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Broad In Vitro Activity Analysis of Tedizolid Compared with Other Agents against a Global Collection of Gram-Positive Isolates Causing Bloodstream Infections (2014–2016)
por: Mendes, Rodrigo E, et al.
Publicado: (2017)

Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Nosocomial- and Community-Acquired Infections in United States Hospitals (2014–2016)
por: Mendes, Rodrigo E, et al.
Publicado: (2017)

264 Results of the Surveillance of Tedizolid Activity and Resistance (STAR) Program: In Vitro Susceptibility of Gram-Positive Clinical Isolates Collected in 2013 From the United States
por: Bien, Paul, et al.
Publicado: (2014)

In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid
por: Zhang, Huiyun, et al.
Publicado: (2022)

In Vitro Activity of Tedizolid, Dalbavancin, and Ceftobiprole Against Clostridium difficile
por: Binyamin, Dana, et al.
Publicado: (2018)

Tedizolid Phosphate: a Next-Generation Oxazolidinone
por: Rybak, Jeffrey M., et al.
Publicado: (2015)

Tedizolid: new data and experiences for clinical practice
por: Lletí, Miguel Salavert, et al.
Publicado: (2021)

Tedizolid-Cyclodextrin System as Delayed-Release Drug Delivery with Antibacterial Activity
por: Paczkowska-Walendowska, Magdalena, et al.
Publicado: (2020)

Single- and Multiple-Dose Pharmacokinetics and Absolute Bioavailability of Tedizolid
por: Flanagan, Shawn, et al.
Publicado: (2014)

Characteristics of Tedizolid Non-susceptible Enterococcal Clinical Isolates
por: Dhand, Abhay, et al.
Publicado: (2017)

Effect of the human endotoxin challenge on tedizolid tissue penetration
por: Jorda, Anselm, et al.
Publicado: (2022)

Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

Stability of crushed tedizolid phosphate tablets for nasogastric tube administration
por: Kennedy, G, et al.
Publicado: (2015)

Stability of Crushed Tedizolid Phosphate Tablets for Nasogastric Tube Administration
por: Kennedy, Gerard, et al.
Publicado: (2015)

Tedizolid clearance by in vitro continuous renal replacement therapy model
por: Lewis, SJ, et al.
Publicado: (2015)

Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy Volunteers
por: Flanagan, Shawn, et al.
Publicado: (2018)

Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?
por: Ruth, Mike Marvin, et al.
Publicado: (2020)

Prolonged tedizolid use in cutaneous non-tuberculous mycobacterial infection
por: Shaw, Timothy David, et al.
Publicado: (2021)

Development and Evaluation of Chitosan Nanoparticles for Ocular Delivery of Tedizolid Phosphate
por: Kalam, Mohd Abul, et al.
Publicado: (2022)

Safety and tolerability of tedizolid as oral treatment for bone and joint infections
por: Miller, Loren G., et al.
Publicado: (2023)

Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages
por: Molina-Torres, Carmen A, et al.
Publicado: (2014)

Tedizolid Activity Against Clinical Mycobacterium abscessus Complex Isolates—An in vitro Characterization Study
por: Tang, Ying Wei, et al.
Publicado: (2018)

1949. Activity of Aztreonam-Avibactam against Enterobacterales Resistant to Recently Approved Beta-Lactamase Inhibitor Combinations Collected Worldwide (ex-US; 2020–2022)
por: Sader, Helio S, et al.
Publicado: (2023)

Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections
por: Urbina, Olatz, et al.
Publicado: (2013)

306. Safety and Tolerability of Tedizolid as Oral Treatment for Bone and Joint Infections
por: Launer, Bryn, et al.
Publicado: (2018)

1289. Assessing the Safety and Efficacy with Prolonged Use of Tedizolid in Orthopedic Patients
por: Garza, Daniel E, et al.
Publicado: (2023)

In vitro activity of tedizolid and linezolid against Staphylococcus epidermidis isolated from prosthetic joint infections
por: Littorin, C., et al.
Publicado: (2017)

327. Oritavancin Activity against Staphylococcus aureus Isolates Causing Bone and Joint Infections in European Hospitals (2010–2019)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

646. Activity of Oritavancin and Comparator Agents Against Coagulase-negative Staphylococci Causing Bloodstream Infections in US Medical Centers (2017-2019)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2022)

Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections
por: Ferrández, Olivia, et al.
Publicado: (2016)

2421. Tedizolid Is Well-Tolerated Among Patients Receiving Prolonged Treatment Courses
por: Marini, Rachel V, et al.
Publicado: (2018)

1578. Rifampicin Reduces Tedizolid Concentrations When Co-Administered in Healthy Volunteers
por: Lee, Lawrence, et al.
Publicado: (2019)

Long-Term Use of Tedizolid in Osteoarticular Infections: Benefits among Oxazolidinone Drugs
por: Benavent, Eva, et al.
Publicado: (2021)

New developments in the management of severe skin and deep skin structure infections – focus on tedizolid
por: Durkin, Michael J, et al.
Publicado: (2015)

Tedizolid vs Linezolid for the Treatment of Nontuberculous Mycobacteria Infections in Solid Organ Transplant Recipients
por: Poon, Yi Kee, et al.
Publicado: (2021)

Perspectives of Positively Charged Nanocrystals of Tedizolid Phosphate as a Topical Ocular Application in Rabbits
por: Alshememry, Abdullah, et al.
Publicado: (2022)

A Retrospective Study to Compare the Incidence of Hyponatremia after Administration between Linezolid and Tedizolid
por: Shibata, Yuichi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bbi059hajmrlgpl2ujk31qne7m